Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan
Haemophilia · 2023-11 · 29 (6) · 1499-1508
DOI: 10.1111/hae.14880 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Haemophilia, online erschienen am 11.10.2023. Verfasst von Ming-Ching Shen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Introduction
Emicizumab mimicking the cofactor function of activated factor VIII (FVIII) restores haemostasis.
Methods
This nationwide observational study aimed to retrospectively investigate efficacy, safety, and cost in 1 year before and up to 3 years after emicizumab prophylaxis for haemophilia A (HA) patients with FVIII inhibitors. Results and discussion A total of 39 severe HA patients with a median age of 23.0 years were enrolled. The median historical peak FVIII inhibitor titre was 174.2 BU/mL with an interquartile range of 56.5–578.8 BU/mL. The median annualized bleeding rate reduced from 24 to 0 events in the first year after emicizumab prophylaxis ( p < .01) and sustained in the second and third years. The median annualized joint bleeding rate reduced to 0 and maintained up to 3 years ( p < .01). Twenty‐seven patients (69.2%) had target joints before emicizumab prophylaxis and only seven patients (17.9%) of them had target joints after prophylaxis. Medical costs, including cost of haemostatic therapy, frequency of outpatient department visits, emergency room visits and hospital admission, were significantly reduced after emicizumab prophylaxis ( p < .01). FVIII inhibitor titre decreased after emicizumab prophylaxis. Overall, three (7.7%) patients experienced 202 grade 1 drug‐related adverse events after emicizumab prophylaxis. No serious adverse events were reported during emicizumab prophylaxis period. The adherence to emicizumab prophylaxis was 100% up to 3 years.
Conclusions
HA patients with FVIII inhibitors treated with emicizumab prophylaxis resulted in a significant reduction in treated bleeds and associated costs. No new safety events were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan.
- Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
ORCID-Profile: Ming-Ching Shen, Sheng-Chieh Chou
Zitieren
APA
Shen, M. C., Chou, S. C., Chiou, S. S., Lin, P. C., Chen, Y. C., Lin, H. Y., Lee, Y. C., Huang, C. E., Weng, T. F., Huang, T. H., Chung, C. Y., Chen, J. S., Chen, S. H., Cheng, S. N., Hsiao, C. C., Huang, Y. M., Chen, S. H., Yu, Y. B., Lin, S. C., …, & Taiwan Society of Thrombosis and Hemostasis study group (2023). Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan. Haemophilia, 29(6), 1499-1508. https://doi.org/10.1111/hae.14880
Vancouver
Shen MC, Chou SC, Chiou SS, Lin PC, Chen YC, Lin HY, et al. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan. Haemophilia. 2023;29(6):1499-1508. doi:10.1111/hae.14880
BibTeX
@article{Shen2023,
author = {Shen, Ming-Ching and Chou, Sheng-Chieh and Chiou, Shyh-Shin and Lin, Pei-Chin and Chen, Yeu-Chin and Lin, Hsuan-Yu and Lee, Yang-Cheng and Huang, Cih-En and Weng, Te-Fu and Huang, Ting-Huan and Chung, Chih-Yuan and Chen, Jiann-Shiuh and Chen, Shu-Huey and Cheng, Shin-Nan and Hsiao, Chih-Cheng and Huang, Yen-Min and Chen, Shih-Hsiang and Yu, Yuan-Bin and Lin, Shih-Chiang and Lin, Ching-Yeh and Peng, Ching-Tien and Wang, Jiaan-Der and Taiwan Society of Thrombosis and Hemostasis study group, Taiwan Society of Thrombosis and Hemostasis study group},
title = {Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan},
journal = {Haemophilia},
year = {2023},
volume = {29},
number = {6},
pages = {1499--1508},
doi = {10.1111/hae.14880}
}
EUVIMED